Silva Pharmaceuticals Limited
|
Nature of business
|
The Company has engaged in manufacturing and marketing of
pharmaceuticals finished products in the categories of Antibiotics,
Analgesics, Anti diabetics, Narcotics, Anti pyretic, Anti-inflammatory
Drugs, Anti ulcerants, Antiemetic, Gastroprokinetic, Anti histamine, Anti
spasmodic expectorants, Vitamins & Minerals medicines which is selling
mainly in local market.
|
|
Reason for IPO
|
Particulars Amount (Tk.)
Acquisition of brand new machinery and
equipment
122,500,000 (40.83%)
Civil construction of two storied new factory
building
56,000,000 (18.67%)
Repayment of term loan 99,000,000 (33.00%)
IPO expenses 22,500,000 (7.50%)
Total 300,000,000 (100%
|
|
Subscription open
|
29 Jul 2018
|
|
Subscription close
|
05 Aug 2018
|
|
Subscription close for NRB
|
29 Jul 2018
to 05 Aug 2018
|
|
Offer price
|
Tk. 10.0
|
|
Face value per share
|
Tk. 10.0
|
|
Market lot
|
500 units
|
|
Single lot price
|
Tk. 5000.0
|
|
EPS
|
Tk. 0.77 for the period ended on March 31, 2018 (Nine Months)
|
|
NAV
|
Tk. 16.94 as on March 31, 2018
|
|
Public offer
|
|
|
Major product
|
The Company has following products:
1. Tablet;
2. Capsule;
3. Liquid &
4. Dry Syrup
|
|
Issue Manager
|
Prime Finance Capital Management Limited Imperial Capital Limited SBL Capital Management Ltd.
|
|
Website
|
http://www.silvapharma.com/
|
